Who
Lantheus Holdings, Inc.
10% owner
Company insider
Files Form 4 as: 10% owner, Perspective Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $845K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 31 Aug 2026
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Sold | $131K42,129 at $3.11 | filing |
| 1 Sep 2026filed 3 Sep 2026 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Sold | $112K35,769 at $3.12 | filing |
| 1 Sep 2026filed 3 Sep 2026 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Sold | $112K35,769 at $3.12 | filing |
| 31 Aug 2026filed 2 Sep 2026 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Sold | $246K78,145 at $3.14 | filing |
| 31 Aug 2026filed 2 Sep 2026 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Sold | $245K78,145 at $3.14 | filing |
News
Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Has Average Target Price of $108.11tickerreport.com · 4 Oct 2026Lantheus Holdings, Inc.: Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY TruVu (piflufolastat F 18)finanznachrichten.de · 30 Sep 2026
2 headlines in the last 90 days name Lantheus Holdings, Inc.; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.